Fol. Biol. 2012, 58, 185-192
https://doi.org/10.14712/fb2012058050185
Low Expression of NQO1 Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Treated with TAC Regimen
References
1. 2010) Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow‐up. Ann. Oncol. 21, (Suppl 5), 9-14.
< , S., Davidson, T., Gruber, G., Castiglione, M. (https://doi.org/10.1093/annonc/mdq159>
2. 2008) HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer. Breast Cancer Res. Treat. 108, 183-190.
< , F., Mazouni, C., Liedtke, C., Kau, S. W., Frye, D., Green, M., Gonzalez‐Angulo, A. M., Symmans, W. F., Hortobagyi, G. N., Pusztai, L. (https://doi.org/10.1007/s10549-007-9594-8>
3. 2007) Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin. Cancer Res. 13, 228-233.
< , A. U., Valero, V., Ibrahim, N. K., Francis, D., Broglio, K. R., Theriault, R. L., Pusztai, L., Green, M. C., Singletary, S. E., Hunt, K. K., Sahin, A. A., Esteva, F., Symmans, W. F., Ewer, M. S., Buchholz, T. A., Hortobagyi, G. N. (https://doi.org/10.1158/1078-0432.CCR-06-1345>
4. 2010) Triple-negative breast cancer: disease entity or title of convenience? Nat. Rev. Clin. Oncol. 7, 683-692.
< , L., Winer, E., Viale, G., Cameron, D., Gianni, L. (https://doi.org/10.1038/nrclinonc.2010.154>
5. 2007) The triple negative paradox: primary tumour chemosensitivity of breast cancer subtypes. Clin. Cancer Res. 13, 2329-2334.
< , L. A., Dees, E. C., Sawyer, L., Gatti, L., Moore, D. T., Collichio, F., Ollila, D. W., Sartor, C. I., Graham, M. L., Perou, C. M. (https://doi.org/10.1158/1078-0432.CCR-06-1109>
6. 2011) The neoadjuvant approach in breast cancer treatment: it is not just about chemotherapy anymore. Curr. Opin. Obstet. Gynecol. 23, 31-36.
< , A. S., Hunt, K. K. (https://doi.org/10.1097/GCO.0b013e3283416477>
7. 1993) Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am. J. Clin. Oncol. 16, 223-228.
< , B., Roche, H., Olivier, J. P., Chollet, P., Hurteloup, P. (https://doi.org/10.1097/00000421-199306000-00006>
8. 2004) Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin. Cancer Res. 10, 6622-6628.
< , M., Viale, G., Zahrieh, D., Pruneri, G., Gentilini, O., Veronesi, P., Gelber, R. D., Curigliano, G., Torrisi, R., Luini, A., Intra, M., Galimberti, V., Renne, G., Nole, F., Peruzzotti, G., Goldhirsch, A. (https://doi.org/10.1158/1078-0432.CCR-04-0380>
9. 2009) Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/ taxane-based chemotherapy. Breast Cancer Res. 11, R69.
< , S., Loibl, S., Muller, B. M., Roller, M., Denkert, C., Komor, M., Schluns, K., Blohmer, J. U., Budczies, J., Gerber, B., Noske, A., du Bois, A., Weichert, W., Jackisch, C., Dietel, M., Richter, K., Kaufmann, M., von Minckwitz, G. (https://doi.org/10.1186/bcr2363>
10. 2010) NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector. Arch. Biochem. Biophys. 501, 116-123.
< , A. T., Talalay, P. (https://doi.org/10.1016/j.abb.2010.03.019>
11. 2008) NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat. Genet. 40, 844-853.
< , R., Hofstetter, B., Tommiska, J., Aaltonen, K., Vrtel, R., Syrjakoski, K., Kallioniemi, A., Kilpivaara, O., Mannermaa, A., Kosma, V. M., Uusitupa, M., Eskelinen, M., Kataja, V., Aittomaki, K., von Smitten, K., Heikkila, P., Lukas, J., Holli, K., Bartkova, J., Blomqvist, C., Bartek, J., Nevanlinna, H. (https://doi.org/10.1038/ng.155>
12. 1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J. Clin. Oncol. 16, 2672-2685.
< , B., Bryant, J., Wolmark, N., Mamounas, E., Brown, A., Fisher, E. R., Wickerham, D. L., Begovic, M., DeCillis, A., Robidoux, A., Margolese, R. G., Cruz, A. B., Jr., Hoehn, J. L., Lees, A. W., Dimitrov, N. V., Bear, H. D. (https://doi.org/10.1200/JCO.1998.16.8.2672>
13. 2009) Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann. Oncol. 20, 1319-1329.
< , A., Ingle, J. N., Gelber, R. D., Coates, A. S., Thurlimann, B., Senn, H. J. (https://doi.org/10.1093/annonc/mdp322>
14. 2004) Lack of association between amplification of her-2 and response to preoperative taxanes in patients with breast carcinoma. Cancer 101, 258-263.
< , A. M., Krishnamurthy, S., Yamamura, Y., Broglio, K. R., Pusztai, L., Buzdar, A. U., Hortobagyi, G. N., Esteva, F. J. (https://doi.org/10.1002/cncr.20348>
15. 2008) Tumour-infiltrating lymphocytes predict response to neoadjuvant chemotherapy in patients with breast carcinoma. Cancer Invest. 26, 1024-1031.
< , H., Melichar, B., Tomsova, M., Mergancova, J., Urminska, H., Ryska, A. (https://doi.org/10.1080/07357900802098165>
16. 2009) NAD(P)H:quinone oxidoreductase 1 Pro187Ser polymorphism and expression do not cosegregate with clinico‐pathological characteristics of human mammary tumours. Pharmacogenet. Genomics 19, 505-512.
< , M., Vaclavikova, R., Mrhalova, M., Kubackova, K., Kodet, R., Gut, I., Soucek, P. (https://doi.org/10.1097/FPC.0b013e32832cf9cf>
17. 2012) Association of superoxide dismutases and NAD(P)H quinone oxidoreductases with prognosis of patients with breast carcinomas. Int. J. Cancer 130, 338-348.
< , M., Vaclavikova, R., Ehrlichova, M., Mrhalova, M., Kodet, R., Kubackova, K., Vrana, D., Gut, I., Soucek, P. (https://doi.org/10.1002/ijc.26006>
18. 2010) Effect of neoadjuvant anthracycline-taxane‐based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study. Breast Cancer Res. Treat. 124, 133-140.
< , J., von Minckwitz, G., Denkert, C., Tesch, H., Weiss, E., Zahm, D. M., Belau, A., Khandan, F., Hauschild, M., Thomssen, C., Hogel, B., Darb‐Esfahani, S., Mehta, K., Loibl, S. (https://doi.org/10.1007/s10549-010-1103-9>
19. 2011) Phase II trial of preoperative chemotherapy for breast cancer: Japan Breast Cancer Research Network (JBCRN)-02 trial. Anticancer Res. 31, 1483-1487.
, S., Yamamoto, D., Kuroda, Y., Kawaguchi, T., Kitamura, K., Odagiri, H., Teramoto, S., Akazawa, K., Nagumo, Y. (
20. 2011) Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy. Pharmacogenet. Genomics 21, 808-819.
< , D., Cresti, N., Bray, J., Sludden, J., Griffin, M. J., Hawsawi, N. M., Famie, E., Mould, E. V., Verrill, M. W., May, F. E., Boddy, A. V. (https://doi.org/10.1097/FPC.0b013e32834b6918>
21. 2011) NQO1 expression correlates inversely with NF-κB activation in human breast cancer. Breast Cancer Res. Treat. 132, 955-968.
< , M., Bartkova, J., Greco, D., Tommiska, J., Fagerholm, R., Aittomaki, K., Mattson, J., Villman, K., Vrtel, R., Lukas, J., Heikkila, P., Blomqvist, C., Bartek, J., Nevanlinna, H. (https://doi.org/10.1007/s10549-011-1629-5>
22. 1999) Clinical course of breast cancer patients with complete pathologic primary tumour and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J. Clin. Oncol. 17, 460-469.
< , H. M., Newman, L. A., Smith, T. L., Ames, F. C., Hunt, K. K., Dhingra, K., Theriault, R. L., Singh, G., Binkley, S. M., Sneige, N., Buchholz, T. A., Ross, M. I., McNeese, M. D., Buzdar, A. U., Hortobagyi, G. N., Singletary, S. E. (https://doi.org/10.1200/JCO.1999.17.2.460>
23. 2011) The changing role of pathology in breast cancer diagnosis and treatment. Pathobiology 78, 99-114.
< , A. S., Zhuang, Z. (https://doi.org/10.1159/000292644>
24. 2011a) ER, PgR, HER-2, Ki-67, topoisomerase IIα, and nm23-H1 proteins expression as predictors of pathological complete response to neoadjuvant chemotherapy for locally advanced breast cancer. Med. Oncol. 28, S48-S54.
< , X. R., Liu, M., Zhang, Y. J., Wang, J. D., Zheng, Y. Q., Li, J., Ma, B., Song, X. (https://doi.org/10.1007/s12032-010-9693-y>
25. 2011b) Evaluation of ER, PgR, HER- 2, Ki-67, cyclin D1, and nm23-H1 as predictors of pathological complete response to neoadjuvant chemotherapy for locally advanced breast cancer. Med. Oncol. 28, S31-S38.
< , X. R., Liu, M., Zhang, Y. J., Wang, J. D., Zheng, Y. Q., Li, J., Ma, B., Song, X. (https://doi.org/10.1007/s12032-010-9676-z>
26. 2004) Prognostic significance of p53, bcl- 2, and Bax expression in early breast cancer. J. Am. Coll. Surg. 198, 83-90.
< , A., Kontogiannea, M., Halwani, F., Edwardes, M., Meterissian, S. (https://doi.org/10.1016/j.jamcollsurg.2003.08.008>
27. 2010) Neoadjuvant therapy for breast cancer. J. Surg. Oncol. 101, 283-291.
< , S. V., Melstrom, L., Yao, K., Russell, C. A., Sener, S. F. (https://doi.org/10.1002/jso.21446>
28. 2006) Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose‐dense sequential adjuvant chemotherapy. Ann. Oncol. 17, 1504-1511.
< , V., Gogas, H., Dafni, U., Bourli, A., Fillipidis, T., Sotiropoulou, M., Vlachodimitropoulos, D., Papadopoulos, S., Tzaida, O., Kafiri, G., Kyriakou, V., Markaki, S., Papaspyrou, I., Karagianni, E., Pavlakis, K., Toliou, T., Scopa, C., Papakostas, P., Bafaloukos, D., Christodoulou, C., Fountzilas, G. (https://doi.org/10.1093/annonc/mdl147>
29. 2003) A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast 12, 320-327.
< , K. N., Miller, I. D., Payne, S., Hutcheon, A. W., Sarkar, T. K., Smith, I., Schofield, A., Heys, S. D. (https://doi.org/10.1016/S0960-9776(03)00106-1>
30. 2008) Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J. Clin. Oncol. 26, 778-785.
< , P., Anderson, S. J., Bear, H. D., Geyer, C. E., Kahlenberg, M. S., Robidoux, A., Margolese, R. G., Hoehn, J. L., Vogel, V. G., Dakhil, S. R., Tamkus, D., King, K. M., Pajon, E. R., Wright, M. J., Robert, J., Paik, S., Mamounas, E. P., Wolmark, N. (https://doi.org/10.1200/JCO.2007.15.0235>
31. 2004) Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br. J. Cancer 91, 2012-2017.
< , A. E., Smith, I. E., Ashley, S., Fulford, L. G., Lakhani, S. R. (https://doi.org/10.1038/sj.bjc.6602235>
32. 2008) Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast 17, 323-334.
< , R., Caldas, C., Pinder, S. E., Pharoah, P. (https://doi.org/10.1016/j.breast.2008.02.002>
33. 2005) Relationship between the expression of cyclooxygenase 2 and MDR1/P-glycoprotein in invasive breast cancers and their prognostic significance. Breast Cancer Res. 7, R862-870.
< , P., Materna, V., Matkowski, R., Szczuraszek, K., Kornafel, J., Wojnar, A., Pudelko, M., Dietel, M., Denkert, C., Zabel, M., Lage, H. (https://doi.org/10.1186/bcr1313>
34. 2011) Neoadjuvant endocrine therapy of breast cancer: which patients would benefit and what are the advantages? Breast Cancer 18, 85-91.
< , H., Kurosumi, M., Yoshida, T., Hayashi, Y., Higuchi, T., Uchida, S., Ninomiya, J., Oba, H., Inoue, K., Nagai, S., Tabei, T. (https://doi.org/10.1007/s12282-010-0239-0>
35. 2010) Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr. Relat. Cancer 17, R245-262.
< , M. T., Dowsett, M. (https://doi.org/10.1677/ERC-10-0136>
36. 2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch. Pathol. Lab. Med. 131, 18-43.
< , A. C., Hammond, M. E., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., McShane, L. M., Paik, S., Pegram, M. D., Perez, E. A., Press, M. F., Rhodes, A., Sturgeon, C., Taube, S. E., Tubbs, R., Vance, G. H., van de Vijver, M., Wheeler, T. M., Hayes, D. F. (https://doi.org/10.5858/2007-131-18-ASOCCO>
37. 2011) Evidence on the association between NQO1 Pro187Ser polymorphism and breast cancer risk in the current studies: a meta-analysis. Breast Cancer Res. Treat. 125, 467-472.
< , W., Xu, L., Chen, W., Wang, L., Fu, Z., Pang, D., Li, D. (https://doi.org/10.1007/s10549-010-0966-0>